Clinical trialNCT01927965CompletedPhase 1Interventional

Study of Minnelide™ in Patients With Advanced GI Tumors

SponsorMinneamrita Therapeutics LLCEnrollment45Advanced Gastrointestinal Tumors

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this study is to determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of Minnelide™ and to establish the dose of Minnelide™ recommended for future phase 2 protocol

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Linda Vocila, BSN
Translational Drug Development
Study Director
clinicaltrials.gov ↗
Mohana Velagapudi, MD
Minneamrita Therapeutics LLC
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Virginia G. Piper Cancer Center at Scottsdale Healthcare
Scottsdale, Arizona, United States
University of Minnesota Masonic Cancer Clinic
Minneapolis, Minnesota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Minnelide™ 001

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2013
Primary completion: 31 Oct 2016
Completion: 31 Dec 2016
Last update posted: 6 Mar 2017
Registered enrollment: 45
Registry id: NCT01927965

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.